

5th PCNE Working Conference
21-24 February 2007

Overcoming the barriers in pharmaceutical care research

Workshop 4

Interprofessional collaboration in pharmaceutical care research

Prof Olivier Bugnon

School of Pharmacy Geneva-Lausanne
Pharmacy of the Policlinique Médicale Universitaire, Lausanne

Prof James C. McElnay

Dean of the Faculty of Medicine, Health and Life Sciences, Belfast

WS4 Participants

Bernsten Cecilia

Björkman Ingeborg

Eickhoff Christiane

Fernandez-Llimos Fernando

Gallego Rosa

Henman Martin

Herborg Hanne

Krass Ines

Krüger Manfred

Modamio Pilar

Salvesen Blix Hege

Vanhecke Sofie

Westh Sörensen Ellen

As workshop leaders:

Mc Elnay James C.

Bugnon Olivier


Overcoming the barriers to interprofessional collaboration in pharmaceutical care research

Aims of the workshop 4...

Through debate, discussion and risk analysis of three case studies:

- prepare a **PCNE guide for risk management of interprofessional issues that can arise in pharmaceutical care research**

Mapping of the actual interprofessional pharmaceutical care research



Disease state management	<ul style="list-style-type: none">• Asthma• Diabetes• Migraine• Heart failure• Elderly• ...
Prevention	<ul style="list-style-type: none">• Medication reviews• DRP / NOM
GPs-pharmacists-nurses-others HCP network	<ul style="list-style-type: none">• Quality circles• Focus groups• Nursing homes• Home care• Seamless care• Pharmacists in GPs office
Screening	<ul style="list-style-type: none">• Risk factors assessment
Adherence	<ul style="list-style-type: none">• Monitoring and intervention programme
Pharmacist prescribing	

A Common Risk Management Process




Result of the SWOT analysis on interprofessional collaboration in pharmaceutical care research

From a pharmacist-centred research to

a primary care-centred research →

- Build a win-win situation for the primary care team
- Research to demonstrate the added value of the pharmacist for the primary care team and vice-versa
- Reinforce new collaborative models, particularly in integrated care and adherence

Description of the global Pharmaceutical care research process :




Risk management grid

Impact	Risk Management Actions		
Significant 3	Considerable management required	Must manage and monitor risks 6	Extensive management essential 9
Moderate 2	Risks may be worth accepting with monitoring	Management effort worthwhile	Management effort required 6
Minor 1	Accept risks	Accept, but monitor risks	Manage and monitor risks
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> Low 1 </div> <div style="text-align: center;"> Medium 2 </div> <div style="text-align: center;"> High 3 </div> </div> <p style="text-align: center; color: purple; font-weight: bold; margin-top: 5px;">Likelihood</p>			

Adapted and modified from

http://www.tbs-sct.gc.ca/pubs_pol/dcgpubs/RiskManagement/rmf-cgr01-1_e.asp#Key%20Concepts



PROJECT MANAGEMENT ACTIVITIES (impact of risk; likelihood of risk)	research stakeholders (3,3 = 9)	Conflicts of interest (3,3 = 9)	patient enrollment (3,3 = 9)	delivering the intervention (3,3 = 9)	recommendations (2,2 = 4)	transfer into practice (3,3 = 9)	Timely delivery (1,1 = 1)
	selection of design, methods and outcomes (3,3 = 9)	communication strategy (3,3 = 9)	baseline data collection (3,1 = 3)	timely delivery (2,3 = 6)	perspectives (2,2 = 4)	lobbying (3,2 = 6)	impact factor
	research team members (2,2 = 4)	non financial resources, incl. goodwill (3,2 = 6)	sites recruitment (3,1 = 3)	study monitoring	statistics	public communication (3,1 = 3)	publications
	strategic development (3,1 = 3)	successful pilot / feasibility study (3,2 = 6)	training (3,1 = 3)	data collection	prospective modeling	scientific publication	fundings
	formulating research question (3,1 = 3)	design of study protocol / materials (2,2 = 4)			results presentation	conferences	other performance indicators
	research funding (2,1 = 2)	environmental scan (2,1 = 2)			limitations	education	successful transfer into practice
	literature phase	budget					PhD
	concept development	ethical approval					
		criteria for study sites inclusion					
		Development of education database					
	timeline / milestones						
	risk assessment						
	statistical design						